Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine,
before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It
also helps stop the patient's immune system from rejecting the donor's stem cells. When the
healthy stem cells from a donor are infused into the patient they may help the patient's bone
marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
transplanted cells from a donor can make an immune response against the body's normal cells.
Giving methylprednisolone and antithymocyte globulin before transplant and peripheral blood
cells that have been treated in the laboratory after transplant may stop this from happening.
PURPOSE: This phase I trial is studying the side effects and best dose of laboratory-treated
peripheral blood cell infusion after donor stem cell transplant in treating patients with
hematologic cancers or other diseases.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
National Cancer Institute (NCI) National Institute of Allergy and Infectious Diseases (NIAID)